Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics

Area of Science:

• Biomaterials Science
• Oncology
• Nanomedicine

Background:

• Significant need for novel therapeutics targeting angiogenesis-dependent calcified neoplasms, including osteosarcomas and bone metastases.
• Development of a dual-targeting strategy using polymer-bound angiogenesis inhibitors.
• Utilized reversible addition-fragmentation chain transfer (RAFT) polymerization to conjugate alendronate (ALN) and TNP-470 with N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer.

Purpose of the Study:

• To develop and evaluate a novel polymer-bound therapeutic conjugate for targeting bone metastases and calcified neoplasms.
• To assess the synergistic anti-angiogenic and anti-tumor effects of co-delivered ALN and TNP-470.
• To investigate the dual targeting capabilities (passive accumulation and active bone targeting) of the developed conjugate.

Main Methods:

• Conjugation of aminobisphosphonate alendronate (ALN) and anti-angiogenic agent TNP-470 to HPMA copolymer via a cathepsin K-cleavable linker.
• In vitro evaluation of anti-angiogenic and anti-tumor activity on endothelial and osteosarcoma cells.
• In vivo assessment of efficacy and biodistribution in SCID mice bearing human osteosarcoma xenografts.

Main Results:

• The HPMA copolymer-ALN-TNP-470 conjugate demonstrated synergistic anti-angiogenic and anti-tumor activity in vitro.
• In vivo studies showed a 92% reduction in VEGF-induced vascular hyperpermeability.
• Remarkable inhibition of osteosarcoma growth by 96% in mice treated with the targeted conjugate.

Conclusions:

• First report of a narrowly-dispersed polymer therapeutic designed for dual targeting of tumor and endothelial compartments in bone metastases and calcified neoplasms.
• Co-delivery of synergistic drugs via this novel approach holds potential clinical utility for angiogenesis-dependent cancers.
• This strategy offers a promising new therapeutic avenue for osteosarcoma and bone metastases.